AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUL 233 min read$ATRC

AtriCure, Inc. (ATRC): Results of Operations and Financial Condition

AtriCure, Inc. (ATRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-7232026.htm EX-99.1 Document Exhibit 99.1 For immediate release July 23, 2026 AtriCure Reports Second Quarter 2026 Financial Results • Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year • Second Quarter 2026 profitabi

Original reporting
SEC EDGAR 8-K
Published Jul 23, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 23, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$ATRC
Bullish
high confidence
Mentioned
$ATRC
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ATRCBullishHigh
01

Why it matters

The combination of Q2 beat on profitability (net income and higher adjusted EBITDA) and explicit FY2026 guidance creates a clear repricing opportunity for ATRC’s growth and margin trajectory.

02

Market read

Traders can update models immediately using the disclosed Q2 datapoints and FY2026 guidance ranges.

03

What to watch

The release emphasizes non-GAAP metrics (adjusted EBITDA/EPS) and mix/manufacturing efficiencies; traders may discount sustainability if gross margin tailwinds reverse.

Relevance 7/10Novelty 9/10Timing: after-hours guidance and Q2 results released via SEC 8-K (July 23, 2026)

Background

This SEC 8-K reports AtriCure’s Q2 2026 results and provides full-year 2026 guidance, including revenue, adjusted EBITDA, and EPS ranges.

Company-level read

Ticker impact

$ATRCBullishHigh confidence
Context

AtriCure reported Q2 2026 revenue of $153.6M (+12.8% YoY), net income of $9.0M, and guided FY2026 revenue to $602M-$610M.

Expected impact

Likely positive near-term bias as traders reprice FY2026 growth and margin expectations; magnitude depends on how the market compares guidance to consensus.

Evidence & confidence

The filing includes fresh, primary financial results and forward guidance ranges (revenue, adjusted EBITDA, EPS) rather than a recap of previously known numbers.

Market effects

Sector

Supports sentiment for cardiac surgery and Afib device peers by signaling demand strength in pain management and appendage management franchises.

Regional

U.S. revenue growth (up 13.6% YoY) suggests domestic procedure volumes and reimbursement conditions are contributing.

Global

International revenue grew 9.6% (7.1% constant currency), indicating some resilience outside the U.S.

Counterpoint

What could challenge this read

Guidance includes a wide revenue range and EPS range; if investors expected a tighter beat, the stock reaction could be muted despite Q2 strength.

Key entities

  • company
    AtriCure, Inc.

    Subject of the 8-K, reporting Q2 2026 financial results and FY2026 guidance.

  • clinical_trials
    BoxX-NoAF and LeAAPS

    Clinical trials referenced as progressing toward data readouts that could influence future growth expectations.

Read at source← All news

Related articles

AUG 8
$DTMedAI 8/10

Dynatrace Springs on Q1 Figures

Dynatrace (NYSE: DT) reported Q1 FY2027 results for the quarter ended June 30, 2026. Total ARR was $2,136 million, up 17%. Total revenue rose to $555 million, up 16%. Subscription revenue was $530 million. GAAP operating income was $71 million and non-GAAP $162 million. CEO Rick McConnell cited 41% organic net new ARR growth and accelerating TTM growth.

baystreet.ca2 min
AUG 8
$DBXMed

Dropbox Shares Decline Despite Earnings Beat as Revenue Growth Disappoints

Dropbox (DBX) shares fell about 5% premarket to around $32.80 after Q2 2026 results. The company reported adjusted EPS of $0.75 vs $0.74 expected and revenue of $631.5M vs about $627M, but revenue rose only 0.9% year over year. Non-GAAP operating margin improved to 39.7%. Paying users reached 18.19M. William Blair upgraded to Market Perform, while consensus remains Sell.

yahoo.com4 min
AUG 8
$HLMedAI 8/10

Hecla Mining Q2 Earnings Call Highlights

Hecla Mining reported Q2 financial and operating updates. The company ended the quarter with $483 million cash, about $472 million net cash, and an essentially undrawn $225 million revolver. It projected 2026 free cash flow of about $500 million at $50 silver and $3,500 gold, and raised Greens Creek silver guidance to 8.0-8.3 million ounces. Production guidance was adjusted for Lucky Friday and Keno Hill.

yahoo.com7 min
AUG 8
$RCELHighAI 9/10

Avita Medical Shares Surge After Record Second-Quarter Performance

Avita Medical (NASDAQ:RCEL) shares rose about 21.7% in premarket after it reported record Q2 results. Revenue was $21.7M, up 18% YoY and about 8% above estimates. Adjusted loss per share narrowed to $0.25 vs $0.30 expected. Full-year 2026 revenue guidance raised to $86M-$89M and cash-flow breakeven targeted for Q4 2026. BTIG upgraded to Buy with a $7.00 target.

yahoo.com4 min
AUG 8
$NETHighAI 9/10

Cloudflare shares jump after forecast raise on higher AI-driven spending

Cloudflare shares rose about 16% premarket after the company raised its full-year outlook, citing higher enterprise spending on AI infrastructure. Cloudflare now forecasts revenue of $2.86B to $2.87B and adjusted EPS of $1.25 to $1.26. Reuters also notes strong cloud growth at Amazon and rising developer additions.

yahoo.com4 min